EUVIMEDEUVIMED entdecken
Leserbrief

Effective treatment of topical corticosteroid‐resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome

Marina Teraoka, Satoru Yonekura iD, Tomoya Takegami, Teruasa Murata iD, Gyohei Egawa iD, Saeko Nakajima iD, Kenji Kabashima iD

The Journal of Dermatology · 2024-11 · 51 (11)

DOI: 10.1111/1346-8138.17311 ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 28.05.2024. Verfasst von Marina Teraoka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Netherton syndrome (NS) is a rare, autosomal recessive disorder characterized by a triad of atopic diathesis, ichthyosiform dermatosis, and hair shaft abnormalities. Recessive loss-of-function mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene lead to impaired skin barrier function.1 A common presenting skin symptom is refractory erythroderma with scaling.1 There are no established treatments for NS,1 and for pediatric cases, safe treatment options are limited. We, herein, report a pediatric case of NS successfully controlled with 0.25% delgocitinib ointment. A 4-year-old Japanese boy, born preterm, presented with scaly erythroderma and bamboo hair. His serum immunoglobulin (Ig) E level was 130 U/mL (normal range T p.Arg790X). Despite the continuous use of moisturizers and strong-class corticosteroid ointment, eczema on the dorsum of both feet remained persistent (Figure 1a,b). After obtaining informed consent, treatment with 0.25% delgocitinib ointment on the dorsum of the right foot, and 0.12% dexamethasone valerate ointment on the dorsum of the left foot, was initiated. After 19 days, the delgocitinib-treated right foot exhibited marked improvement compared with the left foot (Figure 1c,d) with no apparent side effects, such as leukopenia. The underlying genetic defect of SPINK5 in NS triggers the pathogenic cascade, resulting in a defective barrier function.1 The impaired barrier function facilitates the penetration of microbes and allergens, leading to local inflammatory responses and further worsening the barrier function. Therefore, restoring the skin barrier function is crucial in managing NS patients.1 Commonly used topical treatments in NS include corticosteroids.1 However, this option carries a greater risk of systemic absorption and subsequent adverse effects,1 particularly with prolonged and extensive use and especially in refractory cases. Delgocitinib is a pan-Janus kinase (JAK) inhibitor, that suppresses inflammation by blocking various types of cytokine signaling pathways.2 Consistent with our findings on the effectiveness of JAK inhibitors, several case reports have highlighted the efficacy of oral JAK inhibitors in NS.2, 3 Regarding safety, both our case and other cases treated with oral JAK inhibitors reported no apparent adverse effects.2, 3 Notably in our case, topical delgocitinib effectively treated eczematous lesions that were resistant to topical corticosteroids. These corticosteroid-resistant lesions could be attributed to impaired skin-barrier function from long-term use of topical corticosteroids, characterized by reduced gene and protein expressions of tight junctions.4 Conversely, topical delgocitinib has been effective in increasing stratum corneum hydration and reducing transepidermal water loss,5 suggesting it may repair skin-barrier function. In conclusion, our case shows that topical delgocitinib could be a promising option for treating eczema in NS when topical corticosteroids are ineffective. Further studies are warranted to explore the underlying mechanism, safety, tolerability, and long-term efficacy of topical delgocitinib in managing eczema in pediatric NS cases. None declared. The parent of this patient gave written informed consent to publication of the case details.

Autor:innen und Institutionen

  • Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Dermatology, Hyogo Medical University, Hyogo, Japan.
  • Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.

ORCID-Profile: Satoru Yonekura, Teruasa Murata, Gyohei Egawa, Saeko Nakajima, Kenji Kabashima

Zitieren

APA

Teraoka, M., Yonekura, S., Takegami, T., Murata, T., Egawa, G., Nakajima, S., & Kabashima, K. (2024). Effective treatment of topical corticosteroid‐resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome. The Journal of Dermatology, 51(11). https://doi.org/10.1111/1346-8138.17311

Vancouver

Teraoka M, Yonekura S, Takegami T, Murata T, Egawa G, Nakajima S, et al. Effective treatment of topical corticosteroid‐resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome. The Journal of Dermatology. 2024;51(11). doi:10.1111/1346-8138.17311

BibTeX
@article{Teraoka2024,
  author = {Teraoka, Marina and Yonekura, Satoru and Takegami, Tomoya and Murata, Teruasa and Egawa, Gyohei and Nakajima, Saeko and Kabashima, Kenji},
  title = {Effective treatment of topical corticosteroid‐resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome},
  journal = {The Journal of Dermatology},
  year = {2024},
  volume = {51},
  number = {11},
  doi = {10.1111/1346-8138.17311}
}
Kostenlos starten →